nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Pain—Ifosfamide—testicular cancer	0.00168	0.00168	CcSEcCtD
Metolazone—Loss of consciousness—Etoposide—testicular cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Lethargy—Doxorubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Cough—Etoposide—testicular cancer	0.00166	0.00166	CcSEcCtD
Metolazone—Thrombocytopenia—Cisplatin—testicular cancer	0.00165	0.00165	CcSEcCtD
Metolazone—Asthenia—Bleomycin—testicular cancer	0.00165	0.00165	CcSEcCtD
Metolazone—Hyponatraemia—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Metolazone—Hypertension—Etoposide—testicular cancer	0.00164	0.00164	CcSEcCtD
Metolazone—Pruritus—Bleomycin—testicular cancer	0.00162	0.00162	CcSEcCtD
Metolazone—Dry skin—Epirubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Metolazone—Feeling abnormal—Ifosfamide—testicular cancer	0.00162	0.00162	CcSEcCtD
Metolazone—Chest pain—Etoposide—testicular cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Nausea—Vinblastine—testicular cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Orthostatic hypotension—Epirubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Anorexia—Cisplatin—testicular cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Hypokalaemia—Epirubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Metolazone—Gastrointestinal pain—Ifosfamide—testicular cancer	0.0016	0.0016	CcSEcCtD
Metolazone—Pancreatitis—Methotrexate—testicular cancer	0.0016	0.0016	CcSEcCtD
Metolazone—Discomfort—Etoposide—testicular cancer	0.0016	0.0016	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Metolazone—Hypersensitivity—Dactinomycin—testicular cancer	0.00158	0.00158	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—testicular cancer	0.00156	0.00156	CcSEcCtD
Metolazone—Urticaria—Ifosfamide—testicular cancer	0.00156	0.00156	CcSEcCtD
Metolazone—Abdominal pain—Ifosfamide—testicular cancer	0.00155	0.00155	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00154	0.00154	CcSEcCtD
Metolazone—Abdominal distension—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Metolazone—Asthenia—Dactinomycin—testicular cancer	0.00153	0.00153	CcSEcCtD
Metolazone—Paraesthesia—Cisplatin—testicular cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Thrombocytopenia—Etoposide—testicular cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—testicular cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Pancreatitis—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—testicular cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Anorexia—Etoposide—testicular cancer	0.00148	0.00148	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Metolazone—Decreased appetite—Cisplatin—testicular cancer	0.00147	0.00147	CcSEcCtD
Metolazone—Diarrhoea—Dactinomycin—testicular cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Vomiting—Bleomycin—testicular cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—testicular cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Rash—Bleomycin—testicular cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Pain—Cisplatin—testicular cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Dermatitis—Bleomycin—testicular cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Hypersensitivity—Ifosfamide—testicular cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00144	0.00144	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Metolazone—Asthenia—Ifosfamide—testicular cancer	0.00141	0.00141	CcSEcCtD
Metolazone—Photosensitivity reaction—Epirubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Metolazone—Feeling abnormal—Cisplatin—testicular cancer	0.00139	0.00139	CcSEcCtD
Metolazone—Paraesthesia—Etoposide—testicular cancer	0.00139	0.00139	CcSEcCtD
Metolazone—Pruritus—Ifosfamide—testicular cancer	0.00139	0.00139	CcSEcCtD
Metolazone—Pancreatitis—Doxorubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Hyperglycaemia—Epirubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Somnolence—Etoposide—testicular cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Metolazone—Nausea—Bleomycin—testicular cancer	0.00136	0.00136	CcSEcCtD
Metolazone—Drowsiness—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Metolazone—Vomiting—Dactinomycin—testicular cancer	0.00136	0.00136	CcSEcCtD
Metolazone—Agranulocytosis—Methotrexate—testicular cancer	0.00136	0.00136	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Rash—Dactinomycin—testicular cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Decreased appetite—Etoposide—testicular cancer	0.00135	0.00135	CcSEcCtD
Metolazone—Diarrhoea—Ifosfamide—testicular cancer	0.00134	0.00134	CcSEcCtD
Metolazone—Fatigue—Etoposide—testicular cancer	0.00133	0.00133	CcSEcCtD
Metolazone—Neuropathy peripheral—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Metolazone—Constipation—Etoposide—testicular cancer	0.00132	0.00132	CcSEcCtD
Metolazone—Pain—Etoposide—testicular cancer	0.00132	0.00132	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Metolazone—Dizziness—Ifosfamide—testicular cancer	0.0013	0.0013	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Metolazone—Epistaxis—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Metolazone—Feeling abnormal—Etoposide—testicular cancer	0.00128	0.00128	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Nausea—Dactinomycin—testicular cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Agranulocytosis—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Gastrointestinal pain—Etoposide—testicular cancer	0.00127	0.00127	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Vomiting—Ifosfamide—testicular cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Hypersensitivity—Cisplatin—testicular cancer	0.00125	0.00125	CcSEcCtD
Metolazone—Rash—Ifosfamide—testicular cancer	0.00124	0.00124	CcSEcCtD
Metolazone—Dermatitis—Ifosfamide—testicular cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—testicular cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Urticaria—Etoposide—testicular cancer	0.00123	0.00123	CcSEcCtD
Metolazone—Abdominal pain—Etoposide—testicular cancer	0.00122	0.00122	CcSEcCtD
Metolazone—Hepatitis—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Metolazone—Asthenia—Cisplatin—testicular cancer	0.00121	0.00121	CcSEcCtD
Metolazone—Epistaxis—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Metolazone—Agranulocytosis—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Metolazone—Chills—Methotrexate—testicular cancer	0.00117	0.00117	CcSEcCtD
Metolazone—Nausea—Ifosfamide—testicular cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Diarrhoea—Cisplatin—testicular cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Erythema multiforme—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Metolazone—Hypersensitivity—Etoposide—testicular cancer	0.00114	0.00114	CcSEcCtD
Metolazone—Tinnitus—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Metolazone—Hepatitis—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Metolazone—Dysgeusia—Methotrexate—testicular cancer	0.00111	0.00111	CcSEcCtD
Metolazone—Asthenia—Etoposide—testicular cancer	0.00111	0.00111	CcSEcCtD
Metolazone—Back pain—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Metolazone—Chills—Epirubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Metolazone—Pruritus—Etoposide—testicular cancer	0.0011	0.0011	CcSEcCtD
Metolazone—Vomiting—Cisplatin—testicular cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Rash—Cisplatin—testicular cancer	0.00107	0.00107	CcSEcCtD
Metolazone—Dermatitis—Cisplatin—testicular cancer	0.00106	0.00106	CcSEcCtD
Metolazone—Diarrhoea—Etoposide—testicular cancer	0.00106	0.00106	CcSEcCtD
Metolazone—Ill-defined disorder—Methotrexate—testicular cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Tinnitus—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Anaemia—Methotrexate—testicular cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Flatulence—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Tension—Epirubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Dysgeusia—Epirubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Nervousness—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Metolazone—Back pain—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Metolazone—Malaise—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Dizziness—Etoposide—testicular cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Muscle spasms—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Vertigo—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Metolazone—Chills—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Metolazone—Nausea—Cisplatin—testicular cancer	0.001	0.001	CcSEcCtD
Metolazone—Vision blurred—Epirubicin—testicular cancer	0.001	0.001	CcSEcCtD
Metolazone—Cough—Methotrexate—testicular cancer	0.000991	0.000991	CcSEcCtD
Metolazone—Ill-defined disorder—Epirubicin—testicular cancer	0.000987	0.000987	CcSEcCtD
Metolazone—Vomiting—Etoposide—testicular cancer	0.000984	0.000984	CcSEcCtD
Metolazone—Anaemia—Epirubicin—testicular cancer	0.000983	0.000983	CcSEcCtD
Metolazone—Agitation—Epirubicin—testicular cancer	0.000977	0.000977	CcSEcCtD
Metolazone—Rash—Etoposide—testicular cancer	0.000976	0.000976	CcSEcCtD
Metolazone—Dermatitis—Etoposide—testicular cancer	0.000975	0.000975	CcSEcCtD
Metolazone—Headache—Etoposide—testicular cancer	0.00097	0.00097	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—testicular cancer	0.000969	0.000969	CcSEcCtD
Metolazone—Arthralgia—Methotrexate—testicular cancer	0.000967	0.000967	CcSEcCtD
Metolazone—Chest pain—Methotrexate—testicular cancer	0.000967	0.000967	CcSEcCtD
Metolazone—Tension—Doxorubicin—testicular cancer	0.000965	0.000965	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—testicular cancer	0.000963	0.000963	CcSEcCtD
Metolazone—Malaise—Epirubicin—testicular cancer	0.000959	0.000959	CcSEcCtD
Metolazone—Discomfort—Methotrexate—testicular cancer	0.000956	0.000956	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—testicular cancer	0.000956	0.000956	CcSEcCtD
Metolazone—Vertigo—Epirubicin—testicular cancer	0.000955	0.000955	CcSEcCtD
Metolazone—Syncope—Epirubicin—testicular cancer	0.000954	0.000954	CcSEcCtD
Metolazone—Leukopenia—Epirubicin—testicular cancer	0.000952	0.000952	CcSEcCtD
Metolazone—Back pain—Doxorubicin—testicular cancer	0.000952	0.000952	CcSEcCtD
Metolazone—Muscle spasms—Doxorubicin—testicular cancer	0.000946	0.000946	CcSEcCtD
Metolazone—Palpitations—Epirubicin—testicular cancer	0.00094	0.00094	CcSEcCtD
Metolazone—Loss of consciousness—Epirubicin—testicular cancer	0.000935	0.000935	CcSEcCtD
Metolazone—Cough—Epirubicin—testicular cancer	0.000928	0.000928	CcSEcCtD
Metolazone—Vision blurred—Doxorubicin—testicular cancer	0.000927	0.000927	CcSEcCtD
Metolazone—Nausea—Etoposide—testicular cancer	0.00092	0.00092	CcSEcCtD
Metolazone—Hypertension—Epirubicin—testicular cancer	0.000918	0.000918	CcSEcCtD
Metolazone—Ill-defined disorder—Doxorubicin—testicular cancer	0.000913	0.000913	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—testicular cancer	0.000909	0.000909	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—testicular cancer	0.000908	0.000908	CcSEcCtD
Metolazone—Arthralgia—Epirubicin—testicular cancer	0.000905	0.000905	CcSEcCtD
Metolazone—Chest pain—Epirubicin—testicular cancer	0.000905	0.000905	CcSEcCtD
Metolazone—Agitation—Doxorubicin—testicular cancer	0.000904	0.000904	CcSEcCtD
Metolazone—Anxiety—Epirubicin—testicular cancer	0.000902	0.000902	CcSEcCtD
Metolazone—Discomfort—Epirubicin—testicular cancer	0.000894	0.000894	CcSEcCtD
Metolazone—Malaise—Doxorubicin—testicular cancer	0.000887	0.000887	CcSEcCtD
Metolazone—Dry mouth—Epirubicin—testicular cancer	0.000885	0.000885	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—testicular cancer	0.000884	0.000884	CcSEcCtD
Metolazone—Anorexia—Methotrexate—testicular cancer	0.000884	0.000884	CcSEcCtD
Metolazone—Syncope—Doxorubicin—testicular cancer	0.000882	0.000882	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—testicular cancer	0.000881	0.000881	CcSEcCtD
Metolazone—Palpitations—Doxorubicin—testicular cancer	0.000869	0.000869	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—testicular cancer	0.000865	0.000865	CcSEcCtD
Metolazone—Cough—Doxorubicin—testicular cancer	0.000859	0.000859	CcSEcCtD
Metolazone—Shock—Epirubicin—testicular cancer	0.000854	0.000854	CcSEcCtD
Metolazone—Thrombocytopenia—Epirubicin—testicular cancer	0.00085	0.00085	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—testicular cancer	0.000849	0.000849	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000845	0.000845	CcSEcCtD
Metolazone—Insomnia—Methotrexate—testicular cancer	0.000839	0.000839	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—testicular cancer	0.000838	0.000838	CcSEcCtD
Metolazone—Chest pain—Doxorubicin—testicular cancer	0.000838	0.000838	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—testicular cancer	0.000835	0.000835	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—testicular cancer	0.000833	0.000833	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Metolazone—Anorexia—Epirubicin—testicular cancer	0.000827	0.000827	CcSEcCtD
Metolazone—Somnolence—Methotrexate—testicular cancer	0.000824	0.000824	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—testicular cancer	0.000819	0.000819	CcSEcCtD
Metolazone—Dyspepsia—Methotrexate—testicular cancer	0.000816	0.000816	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—testicular cancer	0.000806	0.000806	CcSEcCtD
Metolazone—Fatigue—Methotrexate—testicular cancer	0.000799	0.000799	CcSEcCtD
Metolazone—Pain—Methotrexate—testicular cancer	0.000793	0.000793	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000791	0.000791	CcSEcCtD
Metolazone—Shock—Doxorubicin—testicular cancer	0.00079	0.00079	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—testicular cancer	0.000786	0.000786	CcSEcCtD
Metolazone—Insomnia—Epirubicin—testicular cancer	0.000785	0.000785	CcSEcCtD
Metolazone—Paraesthesia—Epirubicin—testicular cancer	0.000779	0.000779	CcSEcCtD
Metolazone—Somnolence—Epirubicin—testicular cancer	0.000771	0.000771	CcSEcCtD
Metolazone—Anorexia—Doxorubicin—testicular cancer	0.000765	0.000765	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—testicular cancer	0.000764	0.000764	CcSEcCtD
Metolazone—Dyspepsia—Epirubicin—testicular cancer	0.000764	0.000764	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000758	0.000758	CcSEcCtD
Metolazone—Decreased appetite—Epirubicin—testicular cancer	0.000754	0.000754	CcSEcCtD
Metolazone—Fatigue—Epirubicin—testicular cancer	0.000748	0.000748	CcSEcCtD
Metolazone—Pain—Epirubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Metolazone—Constipation—Epirubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Metolazone—Urticaria—Methotrexate—testicular cancer	0.000737	0.000737	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—testicular cancer	0.000733	0.000733	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000732	0.000732	CcSEcCtD
Metolazone—Insomnia—Doxorubicin—testicular cancer	0.000726	0.000726	CcSEcCtD
Metolazone—Paraesthesia—Doxorubicin—testicular cancer	0.000721	0.000721	CcSEcCtD
Metolazone—Feeling abnormal—Epirubicin—testicular cancer	0.000715	0.000715	CcSEcCtD
Metolazone—Somnolence—Doxorubicin—testicular cancer	0.000714	0.000714	CcSEcCtD
Metolazone—Gastrointestinal pain—Epirubicin—testicular cancer	0.00071	0.00071	CcSEcCtD
Metolazone—Dyspepsia—Doxorubicin—testicular cancer	0.000707	0.000707	CcSEcCtD
Metolazone—Decreased appetite—Doxorubicin—testicular cancer	0.000698	0.000698	CcSEcCtD
Metolazone—Fatigue—Doxorubicin—testicular cancer	0.000692	0.000692	CcSEcCtD
Metolazone—Urticaria—Epirubicin—testicular cancer	0.000689	0.000689	CcSEcCtD
Metolazone—Pain—Doxorubicin—testicular cancer	0.000687	0.000687	CcSEcCtD
Metolazone—Constipation—Doxorubicin—testicular cancer	0.000687	0.000687	CcSEcCtD
Metolazone—Abdominal pain—Epirubicin—testicular cancer	0.000686	0.000686	CcSEcCtD
Metolazone—Hypersensitivity—Methotrexate—testicular cancer	0.000683	0.000683	CcSEcCtD
Metolazone—Asthenia—Methotrexate—testicular cancer	0.000665	0.000665	CcSEcCtD
Metolazone—Feeling abnormal—Doxorubicin—testicular cancer	0.000662	0.000662	CcSEcCtD
Metolazone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Metolazone—Pruritus—Methotrexate—testicular cancer	0.000656	0.000656	CcSEcCtD
Metolazone—Hypersensitivity—Epirubicin—testicular cancer	0.000639	0.000639	CcSEcCtD
Metolazone—Urticaria—Doxorubicin—testicular cancer	0.000638	0.000638	CcSEcCtD
Metolazone—Abdominal pain—Doxorubicin—testicular cancer	0.000635	0.000635	CcSEcCtD
Metolazone—Diarrhoea—Methotrexate—testicular cancer	0.000634	0.000634	CcSEcCtD
Metolazone—Asthenia—Epirubicin—testicular cancer	0.000623	0.000623	CcSEcCtD
Metolazone—Pruritus—Epirubicin—testicular cancer	0.000614	0.000614	CcSEcCtD
Metolazone—Dizziness—Methotrexate—testicular cancer	0.000613	0.000613	CcSEcCtD
Metolazone—Diarrhoea—Epirubicin—testicular cancer	0.000594	0.000594	CcSEcCtD
Metolazone—Hypersensitivity—Doxorubicin—testicular cancer	0.000592	0.000592	CcSEcCtD
Metolazone—Vomiting—Methotrexate—testicular cancer	0.00059	0.00059	CcSEcCtD
Metolazone—Rash—Methotrexate—testicular cancer	0.000585	0.000585	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—testicular cancer	0.000584	0.000584	CcSEcCtD
Metolazone—Headache—Methotrexate—testicular cancer	0.000581	0.000581	CcSEcCtD
Metolazone—Asthenia—Doxorubicin—testicular cancer	0.000576	0.000576	CcSEcCtD
Metolazone—Dizziness—Epirubicin—testicular cancer	0.000574	0.000574	CcSEcCtD
Metolazone—Pruritus—Doxorubicin—testicular cancer	0.000568	0.000568	CcSEcCtD
Metolazone—Vomiting—Epirubicin—testicular cancer	0.000552	0.000552	CcSEcCtD
Metolazone—Nausea—Methotrexate—testicular cancer	0.000551	0.000551	CcSEcCtD
Metolazone—Diarrhoea—Doxorubicin—testicular cancer	0.000549	0.000549	CcSEcCtD
Metolazone—Rash—Epirubicin—testicular cancer	0.000547	0.000547	CcSEcCtD
Metolazone—Dermatitis—Epirubicin—testicular cancer	0.000547	0.000547	CcSEcCtD
Metolazone—Headache—Epirubicin—testicular cancer	0.000544	0.000544	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—testicular cancer	0.000531	0.000531	CcSEcCtD
Metolazone—Nausea—Epirubicin—testicular cancer	0.000515	0.000515	CcSEcCtD
Metolazone—Vomiting—Doxorubicin—testicular cancer	0.000511	0.000511	CcSEcCtD
Metolazone—Rash—Doxorubicin—testicular cancer	0.000506	0.000506	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—testicular cancer	0.000506	0.000506	CcSEcCtD
Metolazone—Headache—Doxorubicin—testicular cancer	0.000503	0.000503	CcSEcCtD
Metolazone—Nausea—Doxorubicin—testicular cancer	0.000477	0.000477	CcSEcCtD
